Celltrion, LISCure Biosciences to develop microbiome therapy for Parkinson's disease
Feb 17, 2023
Celltrion announced on Friday that the company has signed a joint research and development contract with LISCure Biosciences for a microbiome-based Parkinson's disease treatment. LISCure Biosciences is a Pangyo-based biotech company that conducts research for microbiome-based treatment for Parkinson's disease. The biotech currently has an oral microbiome drug development pipeline for Parkinson's disease, called LB-P4. Under the contract, the two companies aim to co-develop live bi